(LOS ANGELES, August 29, 2017) – Worldwide Business with kathy ireland® is pleased to announce an exclusive interview with Airway Therapeutics President/CEO Dr. Marc Salzberg and Chief Scientific Officer Dr. Jan Rosenbaum.
Headquartered in Cincinnati, Ohio and created in 2011 as a spin-out of Cincinnati Children’s Hospital Medical Center, Airway Therapeutics has extensive expertise in protein development for applications in the lungs and pediatrics. Airway Therapeutics is currently developing AT-100 (rhSP-D), a investigational product targeting bronchopulmonary dysplasia (BPD) in preterm born babies. BPD is caused by arrested lung development in premature neonates and can lead to death or chronic lung conditions. Today, current therapies lack critical proteins necessary to prevent the onset of BPD. AT-100 is a recombinant form of human surfactant protein-D (rhSP-D). SP-D, absent from current therapies, is a normal protein component of lung surfactant that performs three critical roles in maintaining healthy lung function.
Dr. Salzberg says, “There is a wealth of data available for Surfactant Protein-D in BPD, which reduces the risk for us to develop this drug and enhances the chance and likelihood to get to market.”
Dr. Rosenbaum says that Airway Therapeutics has chosen to focus on BPD in hopes that they can eventually help prevent the condition. She explains, “BPD is the most common disease that affects very, very preterm infants. BPD affects the smallest of preterm infants. These are the babies that can fit in the palm of your hand. They’re the youngest of the preterm infants. BPD is actually a developmental disorder. What happens is that the lung endures insults from various treatments that are given to these babies, and those insults stop the lung development at a very, very delicate transition time in the developmental process. It’s that halting of lung development that gives these babies problems.”
JL Haber, Vice President of Programming for Worldwide Business with kathy ireland®, is proud to feature Airway Therapeutics. He says, “Although you may not have heard of bronchopulmonary dysplasia — or BPD — it’s probably more common than you think. In fact, every year in the United States and Europe, 160,000 preterm babies are at high risk to acquire BPD. For those babies that do get BPD, forty-nine percent will die — and those that survive are left with continued respiratory diseases like pneumonia and asthma. Airway Therapeutics knows this, and they’re doing everything in their power to stop BPD in its tracks. This revolutionary company is at the forefront of the fight against BPD. It is their goal to eventually prevent BPD altogether — and help so many innocent babies by doing so. We are incredibly honored to have Airway Therapeutics on our show.”
About Worldwide Business with kathy ireland®
Worldwide Business with kathy ireland® is a weekly business television program featuring real-world insights from corporate executives from all over the globe which can be viewed on Fox Business Network as part of their sponsored programming lineup, as well as internationally to over 50 countries on Bloomberg International.
Visit www.tvwwb.com for detailed airing schedules or check your local listings.
Company Name: Worldwide Business with kathy ireland
Contact Person: Gila Stern | Communications Director
Phone: 561-325-7700 x529
Country: United States